[{"address1": "170 Harbor Way", "address2": "Suite 300", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 550 3500", "fax": "650 871 8580", "website": "https://vaxart.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.", "fullTimeEmployees": 105, "companyOfficers": [{"maxAge": 1, "name": "Mr. Steven  Lo", "age": 57, "title": "President, CEO & Director", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 879327, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sean N. Tucker Ph.D.", "age": 56, "title": "Senior VP & Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 622439, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James F. Cummings M.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 679943, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raymond D. Stapleton Jr., Ph.D.", "age": 52, "title": "Chief Technology Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edward B. Berg", "age": 59, "title": "Senior VP & General Counsel", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Laurie  Hastings", "title": "Senior Vice President of Human Resources", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shaily Jaini Garg", "title": "Senior Vice President of Clinical Development & Project Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rajesh  Kapoor Ph.D.", "title": "Senior Vice President of Quality", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 6, "overallRisk": 8, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://newsroom.biotapharma.com/", "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.4673, "open": 0.47, "dayLow": 0.4187, "dayHigh": 0.47, "regularMarketPreviousClose": 0.4673, "regularMarketOpen": 0.47, "regularMarketDayLow": 0.4187, "regularMarketDayHigh": 0.47, "exDividendDate": 1352419200, "payoutRatio": 0.0, "forwardPE": -1.0563414, "volume": 1302870, "regularMarketVolume": 1302870, "averageVolume": 1838253, "averageVolume10days": 1902190, "averageDailyVolume10Day": 1902190, "bid": 0.3168, "ask": 0.49, "bidSize": 2, "askSize": 7, "marketCap": 98843384, "fiftyTwoWeekLow": 0.28, "fiftyTwoWeekHigh": 1.07, "priceToSalesTrailing12Months": 2.0855234, "fiftyDayAverage": 0.413, "twoHundredDayAverage": 0.6449, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 77466360, "profitMargins": -1.22633, "floatShares": 226422274, "sharesOutstanding": 228223008, "sharesShort": 14348733, "sharesShortPriorMonth": 13157854, "sharesShortPreviousMonthDate": 1744675200, "dateShortInterest": 1747267200, "sharesPercentSharesOut": 0.0629, "heldPercentInsiders": 0.0104, "heldPercentInstitutions": 0.120790005, "shortRatio": 8.63, "shortPercentOfFloat": 0.0637, "impliedSharesOutstanding": 228223008, "bookValue": 0.2, "priceToBook": 2.1655, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -58122000, "trailingEps": -0.26, "forwardEps": -0.41, "lastSplitFactor": "1:11", "lastSplitDate": 1518566400, "enterpriseToRevenue": 1.634, "enterpriseToEbitda": -1.606, "52WeekChange": -0.4819277, "SandP52WeekChange": 0.1189177, "lastDividendValue": 12.188, "lastDividendDate": 1352419200, "quoteType": "EQUITY", "currentPrice": 0.4331, "targetHighPrice": 8.0, "targetLowPrice": 2.0, "targetMeanPrice": 4.66667, "targetMedianPrice": 4.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 41938000, "totalCashPerShare": 0.184, "ebitda": -48238000, "totalDebt": 20561000, "quickRatio": 0.589, "currentRatio": 0.636, "totalRevenue": 47395000, "debtToEquity": 45.072, "revenuePerShare": 0.218, "returnOnAssets": -0.28899, "returnOnEquity": -1.14743, "grossProfits": -26818000, "freeCashflow": 52168624, "operatingCashflow": -33172000, "revenueGrowth": 8.572, "grossMargins": -0.56584, "ebitdaMargins": -1.01779, "operatingMargins": -0.71541, "financialCurrency": "USD", "symbol": "VXRT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Vaxart, Inc. - Common Stock", "longName": "Vaxart, Inc.", "marketState": "CLOSED", "epsTrailingTwelveMonths": -0.26, "epsForward": -0.41, "epsCurrentYear": -0.29, "priceEpsCurrentYear": -1.4934483, "fiftyDayAverageChange": 0.020099998, "fiftyDayAverageChangePercent": 0.048668277, "twoHundredDayAverageChange": -0.21180004, "twoHundredDayAverageChangePercent": -0.32842305, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.0 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 376929000000, "corporateActions": [], "postMarketTime": 1748648945, "regularMarketTime": 1748635201, "exchange": "NCM", "messageBoardId": "finmb_37819645", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -7.31864, "regularMarketPrice": 0.4331, "postMarketChangePercent": 1.59317, "postMarketPrice": 0.44, "postMarketChange": 0.00690001, "regularMarketChange": -0.0342, "regularMarketDayRange": "0.4187 - 0.47", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1838253, "fiftyTwoWeekLowChange": 0.15309998, "fiftyTwoWeekLowChangePercent": 0.54678565, "fiftyTwoWeekRange": "0.28 - 1.07", "fiftyTwoWeekHighChange": -0.63690007, "fiftyTwoWeekHighChangePercent": -0.5952337, "fiftyTwoWeekChangePercent": -48.19277, "dividendDate": 1518566400, "earningsTimestamp": 1747166400, "earningsTimestampStart": 1754596800, "earningsTimestampEnd": 1754596800, "earningsCallTimestampStart": 1747168200, "earningsCallTimestampEnd": 1747168200, "isEarningsDateEstimate": true, "displayName": "Vaxart", "trailingPegRatio": null, "__fetch_time": "2025-05-31"}]